CMS Secures Exclusive Rights to Market Advanced Intravenous Iron Therapies in China Through 15-Year Partnership with Pharmacosmos
核心洞察
China Medical System Holdings Limited has entered into an exclusive 15-year commercialization agreement with Pharmacosmos A/S for two intravenous iron products, Monofer® and Cosmofer®, in mainland China.
Monofer® represents the first third-generation intravenous iron therapy approved in China, featuring innovative nanostructure technology that enables single-dose full iron replenishment of 1,000 mg or more.
The partnership addresses significant unmet medical needs in China, where iron deficiency anemia affects 20.1% of residents but remains underdiagnosed and undertreated.
China Medical System Holdings Limited (CMS) has secured exclusive commercialization rights for two advanced intravenous iron therapies in mainland China through a strategic 15-year partnership with Danish pharmaceutical company Pharmacosmos A/S. The agreement covers Iron Isomaltoside Injection (Monofer®) and Iron Dextran Injection (Cosmofer®), both originator products already approved for marketing in China and included in the country's National Reimbursement Drug List (NRDL).
Advanced Iron Therapy Portfolio
Monofer® represents a significant therapeutic advancement as the first third-generation intravenous iron therapy approved for marketing in China. The drug features an innovative matrix-like nanostructure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This unique structure enables controlled iron release with low levels of labile iron, contributing to a superior safety profile that includes reduced risk of hypersensitivity reactions and hypophosphatemia.
The therapeutic advantage of Monofer® lies in its ability to deliver high-dose infusions of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This single-dose approach enables full iron repletion in one treatment, significantly reducing the burden on patients and healthcare systems while increasing infusion capacity.
Cosmofer®, a second-generation low-molecular-weight iron dextran injection, complements the portfolio with its established clinical track record. Approved for marketing in mainland China in 2003, Cosmofer® holds the distinction of being the only intravenous iron therapy included in Category A of the NRDL and the only one included in the National Essential Medicines List (NEML). This dual status supports its core role in iron supplementation in primary healthcare settings.
Addressing Significant Medical Need
Iron deficiency and iron deficiency anemia represent substantial global health challenges, with more than 1 billion people living with iron deficiency anemia worldwide, making it one of the leading contributors to the global burden of disease. In China, data from the Fourth National Nutrition Survey indicate that the prevalence of iron deficiency anemia among Chinese residents reaches 20.1%.
Despite this high prevalence, significant gaps exist in diagnosis and treatment. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment. This indicates substantial underdiagnosis and undertreatment of iron deficiency conditions.
The clinical use of intravenous iron in China remains relatively conservative due to insufficient awareness of iron deficiency anemia, patient adherence issues, hospitalization constraints, infusion convenience concerns, and safety considerations regarding intravenous iron therapies. A Chinese real-world study demonstrates that the average total dose of iron sucrose used in iron deficiency anemia patients was approximately 511 mg, significantly lower than the target dose of 1,000 mg.
Strategic Market Position
The partnership positions CMS to address unmet clinical needs across multiple medical specialties. Patients with iron deficiency and iron deficiency anemia are widely distributed across clinical departments including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics—all key specialty areas for CMS.
Monofer® was approved on January 30, 2021, for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug, enhancing patient access to this advanced therapy.
The low risk of hypophosphatemia associated with Monofer® helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anemia. This safety profile, combined with the convenience of single-dose administration, addresses key barriers to optimal iron deficiency treatment.
Partnership Structure
Under the agreement, CMS has obtained exclusive rights to commercialize both products in the People's Republic of China, excluding Hong Kong, Macau, and Taiwan. Pharmacosmos A/S will continue to manufacture and supply the products throughout the 15-year cooperation term, which may be extended upon mutual agreement between the parties.
Pharmacosmos A/S brings significant expertise to the partnership as a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Founded in 1965 and headquartered in Denmark, the company employs more than 700 specialists across multiple countries and has established strong technological capabilities and market reputation through its iron therapy products approved and used worldwide.
The addition of these two products is expected to generate efficient synergies with CMS's existing marketed products in expert resources and academic promotion networks, further strengthening the company's overall competitiveness in the field of anemia treatment and potentially having a positive impact on the group's performance.